8-KThe WireRoutine
Company Update
Filed Apr 13, 2026 · 2mo ago · Accession 0001193125-26-152039
Plain English
Revolution Medicines, Inc. reported topline results from its Phase 3 RASolute 302 clinical trial for daraxonrasib, showing statistically significant improvements in progression-free survival and overall survival compared to standard chemotherapy. The company plans to submit these data to global regulatory authorities.
Filing details
- Company
- Revolution Medicines, Inc.
- Ticker
- RVMD
- CIK
- 1628171
- Form type
- 8-K
- Filing date
- Apr 13, 2026
- Report date
- Apr 13, 2026
- Document
- d69348d8k.htm
- Size
- 171 KB